Gradert Advance @AdvanceGradert

🔥🔒 The Inverse Lock-Up: How $NWBO #DCVax Approval Unleashes a Scarcity Shock #BiggestShort #InverseLockUp $GME $AMC made headlines. #NWBO was kept in silence. One was a meme-stock spectacle. The other is the biggest short hiding in plain sight. @wallstreetbets @MichaelJBurry__…

$NWBO Repost everyone. Make this heard out there! Thanks @kshaughnessy2 🙏

kristen shaughnessy @kshaughnessy2

2 weeks ago

$NWBO Repost everyone. Make this heard out there! Thanks @kshaughnessy2 🙏

16 132 325 26K 16

@peter_brit The July 2025 MHRA newsletter does not mention DCVax or Northwest Biotherapeutics by name, but it strongly alludes to the regulatory and manufacturing model that DCVax is built upon. The newsletter announces that the UK’s new decentralized manufacturing framework officially came…

I've had a great couple of weeks of trading - I sold everything and bought more $NWBO - NWBO has my heart, my complete belief and dedication. Fuck Cancer - I'm all in X2

Thread 🧵 1)"I was pulled over today for speeding. The officer did not know me nor did I know him, but we each showed one another a mutual display of respect in our interaction. He was doing his job, and I had made a mistake in trying to hurry home to get started moving that…

🌕 The Moon Cannot Be Stolen A message from the cockpit of Slave I, where silence is tracking the signal Some people need noise to believe progress is happening. Others mistake $NWBO silence for failure. But in this arena, where law, biology, and precision intertwine, silence…

$NWBO 🧬 TLR3 Agonism, BO‑112, and Hiltonol: The Immune Switch That Rewrites the Tumor’s Code ⏱️ Estimated Read Time: 17–20 minutes 🧬TL;DR: The Tumor Wasn’t Resistant. It Was Invisible. Most “cold” tumors evade immune detection entirely. TLR3 agonists, specifically BO‑112…

$NWBO Approaching Inflection Point once-in-a-generation opportunity as MHRA approval expected within weeks. 1 Positive global trial results for DCVax-L. 2 Peer-Reviewed Results in JAMA 3 Heavy Shorting: Multi-year bear raid suppressed price to penny stock levels.

$NWBO 💡Why Bosch’s Data May Already Justify IFR Access for DCVAX-L 📢 TLDR: MHRA approval may already be complete. The reason it is not yet public could come down to final labeling, platform framing, and global communication strategy. Bosch’s mechanistic data on DCVAX-Direct…

$NWBO 🏊‍♂️ A Swimmer. A Tumor. A System That’s Not Doing Enough. This one hits close. I have two daughters who are competitive swimmers. I have watched them chase qualifying times, hold their breath in pain, and smile through the water like nothing else matters. I know what that…

rj @sharpie510

2 months ago

$NWBO 🏊‍♂️ A Swimmer. A Tumor. A System That’s Not Doing Enough. This one hits close. I have two daughters who are competitive swimmers. I have watched them chase qualifying times, hold their breath in pain, and smile through the water like nothing else matters. I know what that…

1 1 20 3K 0

$NWBO Dear @wesstreeting Sarah Owen @MHRAgovuk , It’s been 15 months since the MAA submission for DCVax-L, a groundbreaking therapy for #GBM one of the deadliest cancers. Still no decision. Still no clarity. DCVax-L delivered the most promising results seen in over 20 years…

$NWBO …and bought more!

This manipulation of $nwbo from shorts and scumbags is gettin silly on this last bear raid....

$NWBO While the price predictions thrown around are large. The approval of DCVAX L implies the further expansion for L and Direct as this MOA is not specific to GBM. And since it was shown that DCVAX can cause an immune response in GBM a typically very hard to treat cancer with…

$NWBO 🧵 Why #NWBO could be the most overlooked biotech breakthrough of the last 20 years For new retail investors, here’s everything you need to know about Northwest Biotherapeutics — and why this tiny company may be on the verge of something enormous. Let's break it down:

$NWBO 2/2He accused the company of being involved in a stock promotion scheme and criticized its management. There is no indication that Andrew Left later retracted or discredited his own claims about Northwest Biotherapeutics. His stance on the company remained critical.

$NWBO 1/2 Andrew Left of Citron Research has been a prominent short seller and is known for his critical reports on various companies. In 2017, he published a report on Northwest Biotherapeutics, alleging misleading practices and financial issues.

APPROVE #NWBO's DCVAX IMMEDIATELY!!! There is no fucking excuse for this!!! investorshub.advfn.com/boards/read_ms…